Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy

Overview

Journal Front Chem

Specialty Chemistry

Date 2021 Jul 22

PMID 34291036

Citations 4

Authors

Minghua Yuan

Yanan Chu

Yongtao Duan

Affiliations

Soon will be listed here.

Abstract

The proteolysis targeting chimeras (PROTACs), which are composed of a target protein binding moiety, a linker, and an E3 ubiquitin ligase binder, have been a promising strategy for drug design and discovery. Given the advantages of potency, selectivity, and drug resistance over inhibitors, several PROTACs have been reported in literature, which mostly focus on noncovalent or irreversible covalent binding to the target proteins. However, it must be noted that noncovalent or irreversible PROTACs have several drawbacks such as weak binding affinity and unpredictable off-target effects. Reversible covalent PROTACs, with properties of enhanced potency, selectivity, and long duration of action, have attracted an increasing amount of attention. Here, we propose a comparison between these three patterns and highlight that reversible covalent PROTACs could pave the way for a wide variety of challenging target degradations.

Citing Articles

Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease.

Alugubelli Y, Xiao J, Khatua K, Kumar S, Sun L, Ma Y J Med Chem. 2024; 67(8):6495-6507.

PMID: 38608245 PMC: 11056980. DOI: 10.1021/acs.jmedchem.3c02416.

A covalent BTK ternary complex compatible with targeted protein degradation.

Schiemer J, Maxwell A, Horst R, Liu S, Uccello D, Borzilleri K Nat Commun. 2023; 14(1):1189.

PMID: 36864023 PMC: 9981747. DOI: 10.1038/s41467-023-36738-z.

Quantitative measurement of PROTAC intracellular accumulation.

Yu X, Wang J Methods Enzymol. 2023; 681:189-214.

PMID: 36764757 PMC: 11102804. DOI: 10.1016/bs.mie.2022.11.001.

Advanced approaches of developing targeted covalent drugs.

Gai C, Harnor S, Zhang S, Cano C, Zhuang C, Zhao Q RSC Med Chem. 2022; 13(12):1460-1475.

PMID: 36561076 PMC: 9749957. DOI: 10.1039/d2md00216g.

References

Xue G, Chen J, Liu L, Zhou D, Zuo Y, Fu T . Protein degradation through covalent inhibitor-based PROTACs. Chem Commun (Camb). 2020; 56(10):1521-1524. DOI: 10.1039/c9cc08238g. View

Gabizon R, Shraga A, Gehrtz P, Livnah E, Shorer Y, Gurwicz N . Correction to Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs. J Am Chem Soc. 2020; 142(25):11316. PMC: 8506570. DOI: 10.1021/jacs.0c05753. View

Gabizon R, London N . The rise of covalent proteolysis targeting chimeras. Curr Opin Chem Biol. 2021; 62:24-33. DOI: 10.1016/j.cbpa.2020.12.003. View

Brennan P, Donev R, Hewamana S . Targeting transcription factors for therapeutic benefit. Mol Biosyst. 2008; 4(9):909-19. DOI: 10.1039/b801920g. View

Bandyopadhyay A, Gao J . Targeting biomolecules with reversible covalent chemistry. Curr Opin Chem Biol. 2016; 34:110-116. PMC: 5107367. DOI: 10.1016/j.cbpa.2016.08.011. View

Kiely-Collins H, Winter G, Bernardes G . The role of reversible and irreversible covalent chemistry in targeted protein degradation. Cell Chem Biol. 2021; 28(7):952-968. DOI: 10.1016/j.chembiol.2021.03.005. View

Lebraud H, Wright D, Johnson C, Heightman T . Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras. ACS Cent Sci. 2017; 2(12):927-934. PMC: 5200928. DOI: 10.1021/acscentsci.6b00280. View

Bondeson D, Smith B, Burslem G, Buhimschi A, Hines J, Jaime-Figueroa S . Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. Cell Chem Biol. 2017; 25(1):78-87.e5. PMC: 5777153. DOI: 10.1016/j.chembiol.2017.09.010. View

Burslem G, Smith B, Lai A, Jaime-Figueroa S, McQuaid D, Bondeson D . The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. Cell Chem Biol. 2017; 25(1):67-77.e3. PMC: 5831399. DOI: 10.1016/j.chembiol.2017.09.009. View

10.

Crew A, Raina K, Dong H, Qian Y, Wang J, Vigil D . Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1. J Med Chem. 2017; 61(2):583-598. DOI: 10.1021/acs.jmedchem.7b00635. View

11.

Hines J, Lartigue S, Dong H, Qian Y, Crews C . MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53. Cancer Res. 2018; 79(1):251-262. PMC: 6318015. DOI: 10.1158/0008-5472.CAN-18-2918. View

12.

Tong B, Luo M, Xie Y, Spradlin J, Tallarico J, McKenna J . Bardoxolone conjugation enables targeted protein degradation of BRD4. Sci Rep. 2020; 10(1):15543. PMC: 7511954. DOI: 10.1038/s41598-020-72491-9. View

13.

Xia L, Ba M, Liu W, Cheng W, Hu C, Zhao Q . Triazol: a privileged scaffold for proteolysis targeting chimeras. Future Med Chem. 2019; 11(22):2919-2973. DOI: 10.4155/fmc-2019-0159. View

14.

Tinworth C, Lithgow H, Dittus L, Bassi Z, Hughes S, Muelbaier M . PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding. ACS Chem Biol. 2019; 14(3):342-347. DOI: 10.1021/acschembio.8b01094. View

15.

Koehler A . A complex task? Direct modulation of transcription factors with small molecules. Curr Opin Chem Biol. 2010; 14(3):331-40. PMC: 3248789. DOI: 10.1016/j.cbpa.2010.03.022. View

16.

Testa A, Lucas X, Castro G, Chan K, Wright J, Runcie A . 3-Fluoro-4-hydroxyprolines: Synthesis, Conformational Analysis, and Stereoselective Recognition by the VHL E3 Ubiquitin Ligase for Targeted Protein Degradation. J Am Chem Soc. 2018; 140(29):9299-9313. PMC: 6430500. DOI: 10.1021/jacs.8b05807. View

17.

Tomoshige S, Hashimoto Y, Ishikawa M . Efficient protein knockdown of HaloTag-fused proteins using hybrid molecules consisting of IAP antagonist and HaloTag ligand. Bioorg Med Chem. 2016; 24(14):3144-8. DOI: 10.1016/j.bmc.2016.05.035. View

18.

Sakamoto K, Kim K, Kumagai A, Mercurio F, Crews C, Deshaies R . Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A. 2001; 98(15):8554-9. PMC: 37474. DOI: 10.1073/pnas.141230798. View

19.

Bondeson D, Mares A, Smith I, Ko E, Campos S, Miah A . Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015; 11(8):611-7. PMC: 4629852. DOI: 10.1038/nchembio.1858. View

20.

Mullard A . First targeted protein degrader hits the clinic. Nat Rev Drug Discov. 2019; . DOI: 10.1038/d41573-019-00043-6. View